证券日报网讯 1月28日，赤峰黄金发布公告称，公司股票交易连续三个交易日（2026年1月26日、1月27 日、1月28日）内日收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动情形。经公司自查并向 控股股东及实际控制人核实，截至本公告披露日，公司不存在应披露而未披露的重大信息。 （编辑 姚尧） ...

Group 1 - The core point of the announcement is that shareholders plan to reduce their holdings in the company due to personal financial needs [1] - The total number of shares to be reduced is up to 7,943,228 shares, which represents approximately 2.59% of the company's total share capital [1] - The reduction will take place within three months after the announcement, starting 15 trading days from the date of disclosure [1]

Group 1 - The company announced the appointment of Lixin Certified Public Accountants (Special General Partnership) as the auditing firm for the fiscal year 2025 [1] - Originally, Mr. Zhao Zhidong and Mr. Hong Jianliang were designated as the signing auditors, but due to a work adjustment for Mr. Zhao, the signing auditors have been changed to Mr. Hong Jianliang and Mr. Li Qingju [1] - The updated signing auditors for the company's 2025 audit project are Mr. Hong Jianliang and Mr. Li Qingju [1]

（编辑 姚尧） 证券日报网讯 1月28日，中国黄金发布公告称，公司股票于2026年1月27日、1月28日连续两个交易日内 日收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动。经公司自查，并征询公司控股股东、实 控人，截至本公告披露日，公司控股股东、实控人确认不存在影响公司股票交易异常波动的重大事项， 不存在涉及公司的应披露而未披露的重大信息。 ...

（编辑 姚尧） 证券日报网讯 1月28日，泽宇智能发布公告称，中汇会计师事务所（特殊普通合伙）（以下简称"中汇 所"）作为公司2025年度财务报告及内部控制审计机构，原委派刘炼为项目合伙人、周永辉为签字注册 会计师、章祥为质量控制复核人为公司提供2025年度审计服务。因原项目合伙人刘炼工作变动，中汇所 现委派于薇薇接替刘炼作为项目合伙人为公司提供2025年度审计服务。 ...

Core Viewpoint - The company, Betta Pharmaceuticals, is advancing two innovative drug candidates aimed at treating specific types of cancer, with a commitment to timely information disclosure regarding significant developments [1]. Group 1: Drug Development - The self-developed BPI-520105 tablets are a new, highly selective pan-EGFR small molecule inhibitor targeting patients with solid tumors carrying epidermal growth factor receptor (EGFR) mutations [1]. - The BPI-572270 capsules are a novel, potent pan-RAS "non-degradable molecular glue" inhibitor intended for the treatment of patients with advanced malignant solid tumors [1]. - Both projects are progressing in accordance with clinical research plans [1].

Core Viewpoint - The company has established an overseas factory in Vietnam as a smart manufacturing base, focusing on high-standard design and construction for automation and warehousing automation [1] Group 1: Factory Development - The first phase of the factory was put into operation in 2023 and is running well [1] - After the first phase reaches full capacity, the investment for the second phase will begin in 2025, with the current phase gradually entering production [1] Group 2: Operational Efficiency - The Vietnam factory has shown good operational efficiency after nearly three years of development [1] - It has become an important foundation for the company's global layout and is capable of handling manufacturing demands beyond the company's main business [1]

Group 1 - The company, Jiukang Bio, announced an expected net profit attributable to shareholders for the year 2025 to be between 180 million and 218 million yuan, representing a decline of 66.21% to 59.07% compared to the previous year's net profit of 532.6353 million yuan [1]

（编辑 姚尧） 证券日报网讯 1月28日，爱美客在互动平台回答投资者提问时表示，公司新品的终端销售、复购率、医 院进货数据等涉及商业和具体经营数据，公司未有单独的披露数据。公司严格按照法律法规的要求履行 信披义务。 ...

Core Viewpoint - The company emphasizes a cautious approach in its earnings forecast, adhering to regulations that limit the range of performance predictions to within 50%, with encouragement to keep it under 30% [1] Group 1: Earnings Forecast - The company has set a narrower performance range than the regulatory maximum, reflecting its prudent operational strategy [1] - The company aims to communicate its investment value to the market through steady operations and fulfilling information disclosure obligations [1] Group 2: Business Strategy - The company focuses on its core business and enhances research and innovation to continuously improve operational performance [1] - The commitment is to create long-term and stable value returns for shareholders [1]